Feng Zhao

PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with <i>EGFR</i> and <i>ERBB2</i> Mutations that Are Resistant to Gefitinib

Jeffrey A. Engelman, Kreshnik Zejnullahu, Christopher-Michael Gale et al. · Cancer Research · 2007 · 713 citations · Full text

Identification of (<i>R</i>)-<i>N</i>-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1<i>H</i>-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas

Rishi G. Vaswani, Victor Gehling, Les A. Dakin et al. · Journal of Medicinal Chemistry · 2016 · 214 citations · Full text

Prognostic influence of metformin as first‐line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes

Benxu Tan, W. Yao, Jun Ge et al. · Cancer · 2011 · 163 citations

An Alternative Approach to ChIP-Seq Normalization Enables Detection of Genome-Wide Changes in Histone H3 Lysine 27 Trimethylation upon EZH2 Inhibition

Brian Egan, Chih-Chi Yuan, Madeleine Craske et al. · PLoS ONE · 2016 · 157 citations · Full text

Histone Modifications, Epigenetic Change, Genetics +22

Identification of EZH2 and EZH1 Small Molecule Inhibitors with Selective Impact on Diffuse Large B Cell Lymphoma Cell Growth

Shivani Garapaty-Rao, Christopher G. Nasveschuk, Alexandre Gagnon et al. · Chemistry & Biology · 2013 · 154 citations

Hematological Malignancy, Tumor Biology, Lymphoid Neoplasia +8